Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation by Egli-Spichtig, Daniela et al.








Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic
kidney disease and non-renal inflammation
Egli-Spichtig, Daniela ; Imenez Silva, Pedro Henrique ; Glaudemans, Bob ; Gehring, Nicole ; Bettoni,
Carla ; Zhang, Martin Y H ; Pastor-Arroyo, Eva M ; Schönenberger, Désirée ; Rajski, Michal ;
Hoogewijs, David ; Knauf, Felix ; Misselwitz, Benjamin ; Frey-Wagner, Isabelle ; Rogler, Gerhard ;
Ackermann, Daniel ; Ponte, Belen ; Pruijm, Menno ; Leichtle, Alexander ; Fiedler, Georg-Martin ;
Bochud, Murielle ; Ballotta, Virginia ; Hofmann, Sandra ; Perwad, Farzana ; Föller, Michael ; Lang,
Florian ; Wenger, Roland H ; Frew, Ian ; Wagner, Carsten A
Abstract: Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis, and its early rise in
patients with chronic kidney disease (CKD) is independently associated with all-cause mortality. Since in-
flammation is characteristic of CKD and associates with increased plasma FGF23 we examined whether
inflammation directly stimulates FGF23. In a population-based cohort, plasma tumor necrosis factor
(TNF) was the only inflammatory cytokine that independently and positively correlated with plasma
FGF23. Mouse models of CKD showed signs of renal inflammation, renal FGF23 expression and elevated
systemic FGF23 levels. Renal FGF23 expression coincided with expression of the orphan nuclear receptor
Nurr1 regulating FGF23 in other organs. Antibody-mediated neutralization of TNF normalized plasma
FGF23 and suppressed ectopic renal Fgf23 expression. Conversely, TNF administration to control mice
increased plasma FGF23 without altering plasma phosphate. Moreover, in Il10-deficient mice with in-
flammatory bowel disease and normal kidney function, plasma FGF23 was elevated and normalized upon
TNF neutralization. Thus, the inflammatory cytokine TNF contributes to elevated systemic FGF23
levels and also triggers ectopic renal Fgf23 expression in animal models of CKD.
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Abstract 48 
Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and its early rise 49 
in patients with chronic kidney disease (CKD) is independently associated with all-cause 50 
mortality. Since inflammation is characteristic for CKD and has been associated with 51 
plasma FGF23 we examined whether inflammation directly stimulates FGF23. In a 52 
population-based cohort, plasma tumor necrosis factor (TNF) was the only inflammatory 53 
cytokine that independently and positively correlated with plasma FGF23. Mouse models 54 
of CKD showed signs of renal inflammation, renal FGF23 expression and elevated 55 
systemic FGF23. Renal FGF23 expression coincided with expression of the orphan 56 
nuclear receptor Nurr1 regulating FGF23 in other organs. Antibody-mediated 57 
neutralization of TNF normalized plasma FGF23 and ectopic renal Fgf23 expression. 58 
Conversely, TNF administration to control mice increased plasma FGF23 without altering 59 
plasma phosphate. Similarly, in Il10 deficient mice with inflammatory bowel disease and 60 
normal kidney function, FGF23 was elevated and normalized upon TNF neutralization. 61 
In conclusion, the inflammatory cytokine TNF contributes to elevated systemic FGF23 62 
levels and triggers also ectopic renal Fgf23 expression in CKD animal models. 63 
Keywords 64 
Fibroblast growth factor 23 (FGF23), tumor necrosis factor (TNF), chronic kidney disease 65 
(CKD), inflammation, cytokine, inflammatory bowel disease, bone. 66 
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INTRODUCTION 68 
Chronic kidney disease (CKD) causes a severe disturbance of mineral metabolism, one 69 
of the leading factors for morbidity and mortality in patients with end stage renal disease 70 
(ESRD) 1, 2. Fibroblast growth factor 23 (FGF23) increases early during CKD progression 71 
and is required to maintain serum phosphate levels while kidney function declines 3. In 72 
CKD patients, high FGF23 levels are associated with an increased risk of mortality 73 
independent of plasma phosphate 4. FGF23 promotes left ventricular hypertrophy in 74 
rodents 5 and elevated FGF23 is a risk factor in the general population for all-cause and 75 
cardiovascular mortality 6. 76 
FGF23 is critical for the regulation of phosphate homeostasis and vitamin D3 metabolism 77 
7. The main target organ of FGF23 is the kidney where FGF23 binds together with 78 
αKlotho to FGF receptors and inhibits phosphate reabsorption and decreases 1,25-(OH)2 79 
vitamin D3 (1,25(OH)2D) 8, 9. FGF23 levels are regulated by a variety of stimuli including 80 
calcitriol, PTH, insulin, aldosterone, erythropoietin, and adipokinines 8, 10-13. Moreover, 81 
FGF23 may be linked to inflammation. In the Chronic Renal Insufficiency Cohort elevated 82 
FGF23 is independently associated with higher IL-6 and TNF 14 and also in a smaller 83 
cohort with only 103 CKD patients, RANTES and IL-12 associated with higher FGF23 15. 84 
The association between FGF23 and inflammation markers is not limited to CKD. The 85 
Reasons for Geographic and Racial Differences in Stroke study found a positive 86 
correlation of FGF23 with IL-6 and IL-10 in a non-CKD population 16. Children during an 87 
acute phase of inflammatory bowel disease (IBD) had elevated FGF23 that normalized 88 
in the remission phase 17. Furthermore, chondrocytes from patients with osteoarthritis 89 
have elevated Fgf23 gene expression 18. Microarray data from mouse models with 90 
FGF23 excess (Col4a3 KO, Hyp, and Fgf23 transgenic mice) show an activation of genes 91 
important in the regulation of the inflammatory response such as transforming growth 92 
factor beta (TGFβ), tumor necrosis factor (TNF) and nuclear factor of kappa light 93 
polypeptide gene enhancer in B-cells (NFκB) 19. Further, inflammatory stimuli and the 94 
hypoxia inducible transcription factor HIF-1 enhance FGF23 expression: TNF and TGFβ2 95 
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increases FGF23 expression in bone cells in vitro and HIF-1, interleukin-1 beta (IL-1β), 96 
lipopolysaccharide (LPS) increase FGF23 expression in vitro and in vivo 20-25. Also, in an 97 
obesity induced model, TNF is necessary for the increase in FGF23 levels 26. Some 98 
inflammatory stimuli, including TNF, may act on Fgf23 transcription via a 16 kb enhancer 99 
element 27. Moreover, in the folic-acid induced AKI model as well as in the adenine CKD 100 
model, genetic ablation of Il-6 reduced the increase in FGF23 28. Thus, inflammatory 101 
cytokines may play an important role at least in the early phase of CKD to induce FGF23. 102 
However, whether TNF is a critical player has not been demonstrated. 103 
Here, we investigated the association between inflammatory cytokines with plasma 104 
FGF23 in a population-based cohort and evaluated the effect of TNF on the regulation of 105 
plasma FGF23 in CKD animal models and in a non-renal inflammation model. 106 
Furthermore, we evaluated the role of hypoxia on Fgf23 gene expression. Our results 107 
demonstrate a critical role for TNF to stimulate FGF23 in models of renal and non-renal 108 
inflammatory diseases. 109 
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Results 111 
Plasma TNF positively correlated with intact FGF23 in the SKIPOGH 112 
population based cohort 113 
The Swiss Kidney Project on Genes in Hypertension (SKIPOGH) is a family and 114 
population-based, multicenter, cross-sectional study including 1131 subjects randomly 115 
selected 29. We assessed the relationship between plasma intact FGF23 (iFGF23) and 116 
parameters of phosphate metabolism, inflammatory cytokines, and iron metabolism while 117 
considering familial correlation. Participants with drugs interacting with calcium, 118 
magnesium and phosphate metabolism, inflammation and iron metabolism or have 119 
diuretic action were excluded. Based on a linear mixed model with family as random 120 
effect, 1,25(OH)2D, 25-(OH) vitamin D3 (25(OH)D), TNF and calcium showed the highest 121 
fixed effects and were considered significant predictors of plasma iFGF23 while holding 122 
all the other variables constant (Figure 1). The standard deviation of the random effect 123 
was low compared to the standard deviation of the residuals (0.26 vs 0.93), which means 124 
that most of the variation in iFGF23 levels was due to the fixed effects (i.e. hormones, 125 
cytokines, etc.). There was no correlation between plasma iFGF23 and plasma 126 
phosphate, PTH, or eGFR. Besides TNF, no other inflammatory cytokine such as 127 
interferon gamma (IFNγ), IL-1β, IL-6, or IL-10 correlated with plasma iFGF23. 128 
We also analyzed the cohort without applying exclusion criteria based on drugs. 129 
1,25(OH)2D, 25(OH)D, and calcium remained as predictors of iFGF23 while phosphate, 130 
PTH and eGFR arose as additional predictors of iFGF23 (Figure S1). TNF effect on 131 
iFGF23 is reduced in this population. 132 
Inflammation in kidneys of Pkd1 conditional KO mice 133 
TNF is increased in CKD patients, stimulates FGF23 expression in an osteocyte cell line, 134 
and was the only inflammatory cytokine associated with iFGF23 in the SKIPOGH cohort 135 
14, 22, 31, 32. Thus, we tested in two CKD mouse models whether TNF contributes to the 136 
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rise of iFGF23 during the early phase of kidney disease. First, slowly progressing 137 
polycystic kidney disease (PKD) was induced in Pkd1 conditional KO mice 33. Kidney 138 
function and two-kidney per body weight ratio were similar in 6 week old mice whereas 139 
kidney function was decreased and two-kidney per body weight ratio was increased in 140 
12 week old Pkd1, cre+ mice (Figure S2). At week 6, iFGF23, TmP/GFR as well as renal 141 
Tnf and Tgfb mRNA expression were similar in Pkd1fl/fl, cre- and Pkd1fl/fl, cre+ mice 142 
(Figure 2 a - d). Progression of kidney disease was accompanied by increased plasma 143 
iFGF23, decreased TmP/GFR as well as increased Tnf and Tgfb mRNA expression in 144 
Pkd1fl/fl, cre+ mice (Figure 2 a - d). TNF binding to TNF receptors activates the NFκB 145 
signaling pathway. The ratio of phospho-NFκB p65 to total NFκB p65 protein in the 146 
nuclear fraction of total kidney was significantly elevated in Pkd1fl/fl, cre+ mice (Figure 2 147 
e). Increased renal inflammatory cytokines in 12 week old Pkd1fl/fl, cre+ mice were 148 
paralleled by the appearance of renal Fgf23 expression and by the upregulation of the 149 
osteogenic marker gene Runx2 (Figure 2 f and S2 e). Bone Fgf23 and Runx2 mRNA 150 
expression were unchanged (Figure 2 g and S2 f). 151 
TNF blockade in Pkd1 conditional KO mice suppressed FGF23 152 
The effect of acute TNF blockade on FGF23 expression in PKD kidneys and on plasma 153 
iFGF23 was investigated. We injected intraperitoneally (i.p.) a single dose of 0.5 mg anti-154 
TNF antibody or isotypic IgG control into 12 week old Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- mice. 155 
After 24 hours, anti-TNF treated mice had a significant reduction of plasma TNF 156 
compared to the IgG control treated mice confirming the efficacy of the anti-TNF antibody 157 
(Figure 3 a). There was no difference in plasma TNF between IgG control treated Pkd1fl/fl, 158 
cre+ and Pkd1fl/fl, cre- mice. Importantly, elevated plasma iFGF23 in Pkd1fl/fl, cre+ mice 159 
was normalized by anti-TNF but not IgG control treatment (Figure 3 b). Plasma C-terminal 160 
FGF23 (cFGF23) was increased in IgG control treated Pkd1fl/fl, cre+ and anti-TNF 161 
treaded Pkd1fl/fl, cre- compared to IgG control treated Pkd1fl/fl, cre- mice consequently 162 
iFGF23/cFGF23 ratio was elevated in IgG control treated Pkd1fl/fl, cre- mice (Figure S4 a 163 
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– c). There was no change in plasma phosphate and urea as well as the abundance of 164 
the sodium dependent phosphate co-transporter NaPi-IIa at the brush border membrane 165 
(BBM) (Figure 3 c - e). In Pkd1fl/fl, cre+ mice, TNF neutralization decreased ectopic renal 166 
Fgf23 mRNA expression while Fgf23 mRNA expression in bone (Figure 3 f and g) and 167 
Tnf, and Tgfb mRNA expression in kidney (Figure 3 h and i) were unchanged. The mRNA 168 
expression of the inflammatory cytokines Il1b and Il6 was elevated in PKD kidneys but 169 
did not change with treatment (Figure S3). 170 
The orphan nuclear receptor Nurr1 is downstream of TNF signaling and activates Fgf23 171 
mRNA expression in rat osteosarcoma cells upon PTH treatment 37, 38. Nurr1 mRNA was 172 
detected in mouse kidney and bone (Figure S5). In the kidney of 12 week old Pkd1fl/fl, 173 
cre+ mice, Nurr1 mRNA expression was upregulated and Nurr1 protein was 174 
predominantly localized in the cell nucleus compared to Pkd1fl/fl, cre- mice where Nurr1 175 
was mainly distributed in the cytoplasm (Figure S6). Further, nuclear Nurr1 staining in 176 
Pkd1fl/fl, cre+ mice was often co-localized with FGF23. 177 
TNF but not hypoxia increased FGF23 levels 178 
We evaluated the effect of systemic TNF administration on plasma iFGF23 therefore we 179 
injected wild type mice for two consecutive days with 2 μg recombinant mouse TNF. After 180 
48-hours, plasma iFGF23 increased while cFGF23 and iFGF23/cFGF23 ratio were 181 
unchanged (Figure 4a and S4 d – f). Furthermore plasma TNF and fractional excretion 182 
of phosphate increased, plasma urea decreased while plasma phosphate and creatinine 183 
levels were unchanged (Figure 4 b - f). In bone and spleen Fgf23 mRNA expression 184 
decreased in TNF injected compared to vehicle injected mice whereas Fgf23 mRNA 185 
expression in thymus and bone marrow was unchanged (Figure 4 g -j). We cultured 186 
primary osteocytes from tibias and femurs of mice 39, 40 for 2 weeks before being 187 
supplemented for 24 hours either with 10 ng/ml TNF or 10 nM 1,25(OH)2D. TNF as well 188 
as 1,25(OH)2D increased Fgf23 mRNA expression (Figure 4 k). TNF and 1,25(OH)2D 189 
decreased the expression of Dmp1 (Figure 4 l). Dmp1 inhibits Fgf23 gene expression 190 
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and loss of DMP1 in patients causes hypophosphatemic rickets due to high FGF23 levels 191 
41. TNF but not 1,25(OH)2D increased the expression of Galnt3 and Nurr1 (Figure 4 m 192 
and n). Galnt3 mediates O-glycosylation of FGF23 preventing proteolytic cleavage of 193 
FGF23 42, 43. 194 
CKD kidneys are commonly affected by hypoxia 44, 45 which was recently suggested to 195 
stimulate FGF23 expression through the hypoxia inducible transcription factor HIF-1 20, 196 
21, 24. We studied in MC3T3-E1 mouse preosteoblasts the effect of hypoxia on Fgf23 gene 197 
expression. MC3T3-E1 did not display intrinsic Fgf23 expression. Nevertheless, after 2 198 
weeks osteogenic differentiation of MC3T3-E1, Fgf23 mRNA expression was induced by 199 
10 nM 1,25(OH)2D. 1,25(OH)2D-induced Fgf23 mRNA expression was completely 200 
repressed by hypoxic conditions (0.2% O2) for 24 or 48 hours and hypoxia alone failed 201 
to trigger Fgf23 expression (Figure S7 a). The upregulation of the HIF-1 target genes 202 
carbonic anhydrase 9 (Car9) and prolyl hydroxylase domain containing protein 2 (Phd2) 203 
confirmed the presence of hypoxia (Figure S7 b and c). Similarly, hypoxia had no effect 204 
on Fgf23 mRNA expression in U2OS rat osteosarcoma and primary osteoblast cells (data 205 
not shown). We analyzed also kidneys of von Hippel-Lindau (Vhl) KO animals 46. Lack of 206 
VHL prevents HIF hydroxylation and degradation and activates hypoxia sensitive genes 207 
47. Neither the kidneys of Vhl KO animals nor primary kidney cells lacking Vhl 48 208 
expressed any detectable Fgf23 (data not shown). 209 
TNF blockade lowers FGF23 levels in mouse models of oxalate nephropathy 210 
and colitis 211 
We expanded our observations to another CKD mouse model, the oxalate nephropathy 212 
model 49. After induction of oxalate nephropathy, 48 hours prior to sacrifice, mice received 213 
a single i.p. injection of 0.5 mg anti-TNF or isotypic IgG control antibodies. IgG injected 214 
oxalate nephropathy mice had elevated plasma iFGF23 compared to control mice and 215 
TNF blockade normalized the elevated plasma iFGF23 in oxalate nephropathy mice 216 
(Figure 5 a). Plasma cFGF23 and iFGF23/cFGF23 did not differ between the groups 217 
TNF stimulates FGF23 
10 
(Figure S4 g – i). Plasma TNF was significantly reduced in the anti-TNF treated groups 218 
confirming the efficacy of the anti-TNF antibody (Figure 5 b). There was no difference in 219 
plasma TNF between IgG control treated oxalate nephropathy and control mice. Renal 220 
Tnf mRNA expression showed a clear trend to increase in oxalate nephropathy mice and 221 
was not affected by the anti-TNF antibody (Figure 5 c). There was no change in plasma 222 
phosphate and urine phosphate per urine creatinine ratio while the renal function 223 
parameters plasma creatinine and urea showed a trend to increase in the oxalate 224 
nephropathy mice (Figure 5 d – g). 225 
To demonstrate that TNF regulates plasma iFGF23 independent from impaired kidney 226 
function, we analyzed a non-renal inflammation model, the Il10 KO mouse developing 227 
spontaneously colitis 50. Twelve to fourteen weeks old Il10 KO mice had elevated plasma 228 
iFGF23 and increased colon Tnf mRNA expression (Figure 6 a and b). After 48 hours of 229 
a single i.p. injection of 0.5 mg anti-TNF or IgG control, anti-TNF treated Il10 KO mice 230 
had reduced plasma iFGF23 compared to IgG treated animals whereas cFGF23 levels 231 
were similar. There was a reduction in the iFGF23/cFGF23 ratio in anti-TNF treated Il10 232 
KO compared to IgG control treated Il10 KO mice (Figure S4 j – l). Anti-TNF treatment 233 
had no effect on plasma phosphate levels (Figure 6 c and d) or kidney function 234 
parameters (Figure 6 e and f). But there was an increase in abundance of NaPi-IIa at the 235 
BBM in Il10 KO mice treated with anti-TNF antibodies compared to IgG control mice 236 
(Figure 6 g) 237 
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Discussion 239 
We provide a novel explanation for high iFGF23 levels in patients with chronic kidney 240 
disease or inflammation of non-renal origin. Our data demonstrate that TNF is positively 241 
and independently associated with plasma iFGF23 in humans. We show that exogenous 242 
TNF stimulates iFGF23 expression both in vivo and in vitro. TNF neutralization 243 
suppresses plasma iFGF23 in two CKD mouse models and triggers renal Fgf23 244 
expression in PKD kidneys. TNF also contributes to high iFGF23 in a model of intestinal 245 
inflammation with normal kidney function. 246 
In humans, TNF levels correlated with plasma iFGF23 in the SKIPOGH multi-centric 247 
population based cohort. Dhayat et al. found in the same cohort associations between 248 
cFGF23 and plasma phosphate, 1,25(OH)2D, 25(OH)D, the ratio of TmP/GFR, age, sex, 249 
and renal function. However, there are relevant differences between both analyses: 1) 250 
we have measured the biologically active iFGF23 and Dhayat et al. 51 used a method that 251 
detects both the intact form and the biologically inactive C-terminal fragment. 2) in 252 
addition to the subjects excluded by Dhayat et al. we excluded individuals taking drugs 253 
interacting with inflammation and subjects without complete data available for all 254 
variables. However, both analyses identified 1,25(OH)2D and 25(OH)D as strong 255 
predictors of FGF23 variation in the SKIPOGH population while the correlation of PTH 256 
and eGFR in our study was dependent on drug exclusion criteria. 257 
TNF increases in kidney disease and associates with CKD progression 14, 31, 32. TNF 258 
stimulates Fgf23 mRNA expression in an osteocyte-derived cell line 22 and may be 259 
involved in obesity induced increases in FGF23 26. We tested the relevance of FGF23 260 
regulation by TNF in pathological situations such as kidney disease or colitis. We used 261 
two distinct CKD mouse models, the Pkd1 conditional KO mouse and the oxalate 262 
nephropathy model. PKD kidneys are affected by inflammation 52, 53 as confirmed by 263 
higher renal Tnf and Tgfb expression as well as enhanced NFκB subunit p65 264 
phosphorylation. Similarly, in oxalate nephropathy the inflammasome is activated and 265 
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various proinflammatory cytokines are released 49, 54. Ectopic renal FGF23 gene and 266 
protein expression occurs in rodents with either diabetic nephropathy, PKD, or 5/6 267 
nephrectomy 34, 55, 56. The increase of renal Tnf and Tgfb mRNA expression in PKD 268 
kidneys was paralleled by the increase in plasma iFGF23 levels, and the appearance of 269 
renal Fgf23 and Runx-2 expression. Renal FGF23 production may promote inflammation 270 
and fibrosis in the affected kidney 35, 36, 57. We did not detect any change in bone Fgf23 271 
mRNA expression or plasma TNF levels in both CKD models. Similarly, in Col4a3 KO 272 
mice, another CKD model, the early rise in plasma FGF23 is not accompanied by 273 
increased Fgf23 expression in bone 58. TNF blockade in both CKD models normalized 274 
plasma iFGF23 levels without changes in plasma phosphate levels. In the PKD model, 275 
TNF neutralization also reduced renal Fgf23 expression. TNF may regulate renal Fgf23 276 
expression through NFκB stimulating orphan nuclear receptor Nurr1 gene expression 38. 277 
Nurr1 mediates the PTH dependent regulation of Fgf23 in bone 37. Nurr1 was upregulated 278 
in PKD kidneys and predominantly localized in the cell nucleus whereas in wild type 279 
kidneys it was localized in the cytoplasm. Nurr1 nuclear localization often overlapped with 280 
renal FGF23 protein expression. Thus, Nurr1 may contribute to renal FGF23 expression. 281 
In patients with CKD, TNF increases with ascending FGF23 quartiles and correlates with 282 
FGF23 levels independent of renal function and measures of mineral metabolism 14. 283 
Likewise, markers of inflammation correlate with ascending FGF23 quartiles in non-CKD 284 
stroke patients 16. Inoculation of mice with LPS or bacteria stimulates serum FGF23 levels 285 
23, 27. In the diabetic nephropathy rat model, renal FGF23 was reduced by ramipril, an 286 
angiotensin-converting enzyme inhibitor 56, which also reduces inflammation 59. Non-287 
renal diseases characterized by inflammation such as inflammatory bowel disease (IBD) 288 
or osteoarthritis are linked to elevated plasma FGF23 17, 18. Patients with IBD or mouse 289 
colitis models show elevated FGF23 levels, lower 1,25(OH)2D and impaired intestinal 290 
phosphate absorption 17, 60-63. These disturbances are partially caused by TNF and in 291 
patients with IBD, TNF neutralizing therapy can reverse some of these abnormalities. We 292 
tested whether inflammation per se without renal disease could increase FGF23. 293 
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Consistently, in Il-10 KO mice, a model of IBD, plasma FGF23 increased and was 294 
reduced by TNF neutralization without affecting renal function parameters. Thus, 295 
extrarenal inflammation also stimulates FGF23 levels in mouse models and may play a 296 
role in humans. 297 
David et al. reported that 6 hours after administration of the inflammatory cytokine IL-1β 298 
only cFGF23 increased while it required 4 days of consecutive IL-1β injections to 299 
increase also iFGF23 levels 24, whereas Onal et al showed higher FGF23 levels already 300 
3 hours after IL-1 injection 27. We demonstrate that TNF administration in wild type mice 301 
stimulated plasma iFGF23 levels within 48 hours without altering plasma phosphate and 302 
creatinine but increasing fractional excretion of phosphate demonstrating that iFGF23 is 303 
functional. TNF may exert even faster effects as indicated by higher FGF23 levels in mice 304 
3 hours after TNF injection 27. The stimulation of Fgf23 mRNA expression by TNF was 305 
confirmed in vitro in primary mouse osteocytes and comparable to the effect of 306 
1,25(OH)2D. TNF but not 1,25(OH)2D increased Nurr1 and Galnt3 expression in primary 307 
osteocytes suggesting that TNF but not 1,25(OH)2D may regulate Fgf23 expression in a 308 
Nurr1-dependent manner. TNF may also modulate FGF23 protein stability by regulating 309 
the expression of Galnt3 which mediates the O-glycosylation of FGF23 making it more 310 
resistant to proteolytic degradation 43. In bone, C-terminal DMP-1 binds to PHEX and 311 
thereby inhibits Fgf23 expression 64. In primary osteocytes, Dmp1 expression was 312 
strongly decreased by TNF and 1,25(OH)2D. The upregulation of Fgf23 expression by 313 
TNF and 1,25(OH)2D is paralleled by the downregulation of its suppressor. Our data 314 
expand previous observations in IDG-SW3 mouse osteocyte cells where TNF, IL-1β, and 315 
LPS increased Fgf23 and reduced Dmp1 mRNA expression 22. TNF also stimulated 316 
Fgf23 mRNA expression in rat UMR106 osteosarcoma cells and is required to increase 317 
circulating FGF23 levels in a mouse obesity model 25. Deletion of an 16kb enhancer 318 
element in the Fgf23 murine gene abolishes TNF induced FGF23 increases and reduces 319 
the effect of LPS and IL-1 on circulating FGF23 levels without altering bone structure or 320 
plasma phosphate and PTH. Induction of Fgf23 mRNA in various organs is organ-321 
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specifically responsive to LPS, TNF and IL-1β and the deletion of the enhancer 322 
suggesting a complex and cell- and/or organ-specific regulation 27. The enhancer 323 
element is also required for the early induction of FGF23 in the oxalate nephropathy 324 
model 27. Thus, our work demonstrates the critical role of TNF in inducing FGF23 325 
production and thereby complements previous work that identified a genetic element 326 
responding to TNF and possibly other regulators of Fgf23 mRNA transcription 27. 327 
Furthermore, we expand these observations from kidney disease to at least one other 328 
clinically important condition, inflammatory bowel disease.  329 
IL-6 has been recently identified as another important proinflammatory cytokine that 330 
associates with FGF23 levels in the CRIC cohort 14 and that stimulates Fgf23 mRNA in 331 
the IDG-SW3 osteocyte cell line 22. Durlacher-Betzer et al. showed increased expression 332 
of IL-6 in kidney of folic-acid and adenine AKI and CKD mouse models and a partly 333 
blunted increase of circulating FGF23 levels in Il-6 deficient mice treated with adenine 28. 334 
While IL-6 may participate in the regulation of FGF23 in CKD, IL-6 plays also an important 335 
role in normal bone biology and IL-6 deficient mice have altered bone architecture 65, 66. 336 
Thus, IL-6 may contribute to the upregulation of FGF23 in early CKD but TNF may act 337 
either upstream or is a critical permissive factor as indicated by the complete 338 
normalization of FGF23 levels in our experiments. In our population-based cohort, TNF 339 
but not IL-6 associated with intact FGF23 levels further strengthening the concept that 340 
TNF may play a central role in mediating effects of inflammation on bone.  341 
Renal hypoxia is a common complication in CKD kidneys 44, 45. Hypoxia increased Fgf23 342 
expression in UMR-106 rat osteosarcoma cells, and plasma cFGF23 but not iFGF23 in 343 
rats under hypobaric hypoxia conditions 21. We cultured MC3T3-E1 cells, a mouse 344 
preosteoblast cell line and primary mouse osteoblasts for 24 and 48 hours in 0.2% 345 
hypoxia and we did not observe any stimulation of Fgf23 expression. In contrast, hypoxia 346 
suppressed the stimulatory effect of 1,25(OH)2D on Fgf23. TNF and IL-1β increase HIF-347 
1 binding to DNA under normoxia while in combination with hypoxia both cytokines 348 
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strongly increase HIF-1 activity 67. IL-1β but not TNF enhance nuclear accumulation of 349 
HIF-1α in a hepatoma cell line 67 and increase FGF23 mRNA expression in bones and 350 
kidneys 24. Inhibition of HIF-1α attenuated the positive effect of IL-1β on FGF23 351 
expression 24. Combined with the fact that we did not find any effect of constitutively 352 
activated HIF-1α in Vhl KO animals as well as in primary kidney cells lacking Vhl, these 353 
results suggest that the HIF-1α mediated upregulation of Fgf23 expression may depend 354 
on IL-1β or other factors such as erythropoietin 11, 24, 68, 69. 355 
In summary, TNF stimulates iFGF23 in renal and non-renal inflammatory mouse models 356 
and in primary bone cell culture; triggers renal Fgf23 expression in CKD animal models 357 
and is positively associated with plasma iFGF23 in a population-based cohort. These 358 
findings question the concept that the early rise in plasma FGF23 in CKD is solely to 359 
balance plasma phosphate while kidney function declines or if other non-renal processes 360 
may strongly impact on plasma FGF23 levels. Our study suggests novel therapeutic 361 
options to reduce excessive FGF23 levels in kidney and other diseases as drugs lowering 362 
TNF are widely clinically used and have proven to be safe in humans. 363 
  364 
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Methods 365 
SKIPOGH cohort 366 
We obtained 1098 out of 1131 human EDTA plasma samples from SKIPOGH cohort 367 
(Swiss Kidney Project on Genes in Hypertension) 29, 70, 71. Plasma iFGF23 was measured 368 
with the human intact FGF23 ELISA kit (Immutopics International, USA). For statistical 369 
modeling the following 18 previously determined parameters were used: plasma calcium, 370 
phosphate, ferritin, transferrin, iron, 1,25(OH)2D, 25(OH) vitamin D3, PTH, TNF, IFNγ, IL-371 
1β, IL-6, IL-10 and cFGF23 as well as body mass index, age, sex and estimated renal 372 
function calculated by the CKD-EPI equation. 373 
Exclusion criteria followed the pipeline described in the Table S3. Participants with 374 
incomplete data sets (n = 261) were excluded. TNF followed a bimodal distribution with 375 
40 values close to undetectable (TNF < 1 pg/ml) without continuity with the rest of the 376 
distribution, highly suggestive for measurement failures. Therefore the 40 participants 377 
with TNF < 1 pg/ml were excluded from the study. Next, the ratio between iFGF23 378 
(detects only iFGF23) and cFGF23 (detects iFGF23 and cFGF23) was calculated. One 379 
Ru/ml cFGF23 corresponds to 1.5 pg/ml iFGF23 (information provided by Immutopics); 380 
participants with ratios higher than 1.5 were excluded (n = 40). To avoid confounding 381 
effects by drug intake we eliminated 4 major drug categories that interact with FGF23 382 
metabolism: 1) calcium, phosphate and magnesium (n = 41); 2) inflammation (pro or anti-383 
inflammatory) (n = 390); 3) iron metabolism (n = 6); 4) kidney function (i.e. diuretics) (n = 384 
54) (Table S4). A total of 361 participants were excluded due to intake of drugs of one or 385 
more of these drug categories. The final dataset contains either 429 participants (198 386 
female / 231 male) with or 790 (424 female / 366 male) without drug exclusion criteria. 387 
Animals 388 
Pkd1 floxed/floxed (Pkd1fl/fl) tamoxifen inducible cre mice were kindly provided by 389 
Gregory Germino 33, 72. Cre recombinase expression is under the control of the β-actin 390 
promoter which drives high levels of expression in most tissues 33. Male and female 391 
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Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- mice were used. Cre recombinase activity was induced at 392 
postnatal days 15, 17, and 19 by injecting pups with 100 μl tamoxifen (2.5 mg/ml) in corn 393 
oil causing slow onset disease 33. Without further interventions, 24-hour urine was 394 
collected from 6 and 12 weeks old animals (e.g. 3 or 9 weeks after induction, respectively) 395 
which were thereafter sacrificed to collect plasma and organs. For TNF blockade, animals 396 
were treated at the age of 11-12 weeks with a single i.p. injection of 0.5 mg InVivoMAb 397 
anti-Tnfα (Clone XT3.11, Lot4653-1/0413, BioXCell, USA) or InVivoMAb rat IgG1 (Clone 398 
HRPN, Lot 5339/1014, BioXCell, USA) 73, 74. Twenty-four hours after antibody application, 399 
animals were sacrificed and plasma and organs were collected. The effect of TNF in wild-400 
type mice was assessed by injecting 13 weeks old C57Bl/6J mice on two consecutive 401 
days with 2 μg TNF. After 48 hours, plasma and organs were collected.  402 
Nephropathy was induced in 10 to 12 weeks old C57Bl/6J mice. After 3 days of 403 
adaptation with calcium-free diet (irradiated S7042-E005S, Sniff Spezialdiäten GmbH, 404 
Germany), mice were fed for 10 days with either calcium free diet or 0.67% oxalate in 405 
calcium-free diet (irradiated S7042-E010) followed by a 5-day recovery phase in standard 406 
diet (3433, Kliba, Kaiseraugst, Switzerland). Forty-eight hours prior to sacrifice, mice 407 
received a single i.p. injection of 0.5 mg anti-TNF or isotypic IgG1 control. Mice were 408 
sacrificed and plasma and organs were collected. 409 
Il10 deficient mice (Il10-/-) develop spontaneous colitis and were used as a non-renal 410 
inflammatory disease model 50. Il10-/- mice between 12-14 weeks were sacrificed to 411 
collect plasma and organs. Il10-/- mice were treated with a single i.p. injection of 0.5 mg 412 
InVivoMAb anti-Tnfα (Clone XT3.11, Lot4653-1/0413, BioXCell, USA) or InVivoMAb rat 413 
IgG1 (Clone HRPN, Lot 5339/1014, BioXCell, USA) 73, 74 48 hours prior to sacrifice and 414 
plasma and organs were collected. For some experiments, kidneys from kidney-specific 415 
von-Hippel-Lindau deficient mice were used 46. All animal studies were performed 416 
according to protocols approved by the legal authority (Veterinary Office of the Canton 417 
of Zurich or the Committee on Animal Research, University of California San Francisco). 418 
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Plasma and urine analysis 419 
Blood and 24 hours urine were collected from Pkd1fl/fl, cre+ and Pkd1fl/fl, cre- mice at 6 420 
and 12 weeks after birth. Briefly, Pkd1fl/fl, cre mice were kept for three days in metabolic 421 
cages (Tecniplast, Italy) whereas the last day was used for 24 hours urine collection. 422 
Afterwards mice were anesthetized with isoflurane and blood was collected from the 423 
heart. Plasma and urine aliquots were rapidly frozen and stored at -80 ∘ C until 424 
measurement. Urine and plasma laboratory analyses were performed on a UniCel DxC 425 
800 Synchron (Beckman Coulter, Switzerland) by the Zurich Integrative Rodent 426 
Physiology (ZIRP) core facility. The ratio of the maximum rate of tubular phosphate 427 









] where PP, UP, Pcrea, and Ucrea refer to the 429 
plasma and urinary concentration of phosphate and creatinine, respectively 75. The 430 
plasma concentration of intact FGF23 (Kainos Laboratories, Japan or Immutopics 431 
International, USA), intact PTH (Immutopics International, USA) and TNF (Bio-Techne 432 
AG, Switzerland) were measured by enzyme-linked immunosorbent assays according to 433 
the manufacturers protocols. 434 
Cell culture 435 
All cell culture reagents were from Life Technologies Europe B.V. (Switzerland) unless 436 
stated otherwise. Two to four month old Pkd1fl/fl, cre mice (4-6 mice per experiment, male 437 
and female mixed) were sacrificed with carbon dioxide. Tibias and femurs from the 438 
hindlegs were harvested. The epiphyses were cut and bones were flushed with Hank’s 439 
Balanced Salt Solution (HBSS) containing 1% penicillin streptomycin (Pen Strep) to 440 
remove the bone marrow. Bones were cut into small pieces of 1-2 mm2. Bone cell 441 
extraction was performed according to established protocols 39, 40. Briefly, small bone 442 
pieces were repeatedly digested with either a solution containing 2 mg/ml collagenase 443 
type II, 0.05% (w/v) soybean trypsin inhibitor (Sigma-Aldrich, Switzerland), 20 mM 444 
HEPES, 1% Pen Strep in HBSS or 10 nM EDTA, 1% fetal bovine serum (FBS), 1% Pen 445 
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Strep in phosphate buffered saline (PBS) for 25 min at 37°C. Cells from digestion steps 446 
6-9 or cells and bone pieces from digestion step >9 were cultured for 2 weeks in an 447 
osteogenic medium (minimal essential medium α (memα) containing 10% FBS, 1% Pen 448 
Strep, 50 μg/ml 2-phospho-L-ascorbic acid trisodium salt (Sigma-Aldrich, Switzerland), 449 
and 1 mM β-glycerophosphate (Sigma-Aldrich, Switzerland)). After 2 weeks, cells were 450 
supplemented for 24 hours with either 10 nM 1,25(OH)2D (CaymanChemical, USA) or 10 451 
ng/ml mouse TNF (R&D Systems, USA) and total mRNA was extracted. 452 
MC3T3-E1 subclone 4 preostoblast cells (CRL-2593, Lot 59899932, ATCC France) 453 
passage 17/4 were expanded for 4-5 days with MEMα medium supplemented with 10% 454 
FBS and 1% PenStrep. After reaching 80-90% confluence, MC3T3-E1 cells were 455 
trypsinized and plated in collagen coated 6-well plates (80’000 cells/well). Medium was 456 
changed to osteogenic differentiation medium (MEMα supplemented with 10% FBS, 1% 457 
PenStrep, 50μg/ml 2-phospho-L-ascorbic acid trisodium salt (Sigma-Aldrich, 458 
Switzerland), and 1 mM beta glycerophosphate (Sigma-Aldrich, Switzerland)). After 2 459 
weeks differentiation along the osteogenic lineage cells were supplemented for 24 or 48 460 
hours with either 10 nM 1,25(OH)2D (CaymanChemical, USA) or an equal amount of 461 
ethanol and incubated for 24 or 48 hours under hypoxic (0.2% O2) or normoxic conditions. 462 
Hypoxia experiments were performed in a gas-controlled workstation (InvivoO2, Baker 463 
Ruskinn, UK). 464 
RNA extraction, reverse transcription and qPCR 465 
Organs and scraped colonic mucosa were harvested and rapidly frozen in liquid nitrogen. 466 
Tissues were homogenized using either a Precellys homogenizer or a liquid nitrogen 467 
cooled mortar and pestle (bone). Total mRNA from bone as well as from cultured cells 468 
was extracted with TRIzol (Life Technologies Europe B.V., Switzerland) followed by 469 
purification with RNeasy Mini Kit (Qiagen, Switzerland) according to the manufacturers 470 
protocol. Total mRNA from kidney and colonic mucosa were extracted with RNeasy Mini 471 
Kit (Qiagen, Switzerland) according to the manufacturer’s protocol. DNAse digestion was 472 
performed using the RNase-free DNAase Set (Qiagen, Switzerland). Total RNA 473 
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extractions were analyzed for purity and concentration using the NanoDrop ND-1000 474 
spectrophotometer (Wilmington, Germany). RNA samples were diluted to a final 475 
concentration of 100 ng/μl and cDNA was prepared using the TaqMan Reverse 476 
Transcriptase Reagent Kit (Applied Biosystems, Roche, Foster City, CA). In brief, in a 477 
reaction volume of 40 μl, 300 ng of RNA was used as template and mixed with the 478 
following final concentrations of RT buffer (1x): MgCl2 (5.5 mmol/l), random hexamers 479 
(2.5 μmol/l), dNTP mix (500 μmol/l each), RNase inhibitor (0.4 U/μl), multiscribe reverse 480 
transcriptase (1.25 U/μl), and RNAse-free water. Reverse transcription was performed 481 
with temperature conditions set at 25∘C for 10 min, 48∘C for 30 min, and 95∘C for 5 min 482 
on a thermocycler (Biometra, Germany). Quantitative PCR (qPCR) was performed on 483 
the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Primers for 484 
genes of interest were designed using Primer 3 software. Primers were chosen to span 485 
exon - exon boundaries to exclude the amplification of contaminating genomic DNA 486 
(primer and probe sequence see Table S5). The specificity of all primers was tested and 487 
always resulted in a single product of the expected size (data not shown). Probes were 488 
labeled with the reporter dye FAM at the 5’-end and the quencher dye TAMRA at the 3’-489 
end (Microsynth, Switzerland). qPCR reactions were performed using the KAPA PROBE 490 
FAST qPCR Kit (KappaBiosystems, USA) or PowerUpTm SYBR® Green Master Mix 491 
(Applied Biosystems, Switzerland). 492 
Protein extraction and Western blot analysis 493 
Organs were rapidly frozen in liquid nitrogen. Tissues were homogenized in 494 
homogenization buffer containing 0.27 M sucrose, 2 mM EDTA (pH8), 0.5% NP-40, 60 495 
mM KCl, 15 mM NaCl, 15 mM HEPES (pH7.5) (all Sigma-Aldrich, Switzerland) and 496 
complete protease inhibitor cocktail (Roche, Switzerland) using Precellys homogenizer. 497 
Nuclei were separated by a sucrose cushion and resuspended in a nuclear extraction 498 
buffer containing 20 mM HEPES (pH 7.5), 400 mM NaCl, 1 mM EDTA (pH 8), 1 mM DTT 499 
and 1 mM PMSF (all Sigma-Aldrich, Switzerland). After measurement of protein 500 
concentration (Bio-Rad, Hercules, CA, USA), 60 μg of nuclear proteins were solubilized 501 
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in loading buffer containing DTT and separated on a 10% polyacrylamide gel. For 502 
immunoblotting, proteins were transferred electrophoretically to polyvinylidene fluoride 503 
membranes (Immobilon-P, Millipore, Bedford, MA, USA). After blocking with 5% milk 504 
powder in Tris-buffered saline/0.1% Tween-20 or 5% bovine serum albumin (BSA) in 505 
Tris-buffered saline/0.1% Tween-20 for 60 min, blots were incubated with the primary 506 
antibodies: mouse monoclonal anti-phospho-NFκB p65 (Ser536)(7F1) (Cell Signaling 507 
Technology, USA; 1:1000) or rabbit monoclonal NFκB p65 (D14E12) (Cell Signaling 508 
Technology, USA; 1:1000) either for 2 h at room temperature or overnight at 4 ∘C. 509 
Membranes were then incubated for 1 h at room temperature with secondary goat anti-510 
rabbit or donkey anti-mouse antibodies (1:5000) linked to alkaline phosphatase 511 
(Promega, USA) or HRP (Amersham, MA, USA or R&D Systems, USA). The protein 512 
signal was detected with the appropriate substrates using the DIANA III-513 
chemiluminescence detection system (Raytest, Straubenhardt, Germany). All images 514 
were analyzed using the software Advanced Image Data Analyser AIDA, Raytest to 515 
calculate the ratio between phosphorylated protein to total protein. 516 
Immunofluorescence staining 517 
Mouse kidneys were perfused through the left heart ventricle with a fixative solution 518 
containing 3% paraformaldehyde in phosphate buffered saline (PBS). Kidneys were 519 
embedded in TissueTec and frozen in liquid nitrogen. Five μm cryosections were cut. 520 
Slides were rehydrated with PBS, treated for 5 min with 0.5% SDS in PBS followed by 521 
10 min treatment with 0.5% Triton-X-100 in PBS (Sigma-Aldrich, Switzerland). Unspecific 522 
sites were blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at room 523 
temperature. Primary antibodies were diluted in 1% BSA in PBS (rat anti-FGF23 clone 524 
#283507 (R&D Systems, USA) 1:1000; rabbit anti-Nurr1 N-20 sc-991 (Santa-Cruz, USA) 525 
1:200) and kidney sections were incubated with the primary antibody overnight at 4∘C. 526 
After washing with PBS, sections were incubated with the corresponding secondary 527 
antibody (1:500) (anti-rabbit DyLight 594 (Jackson ImmunoResearch, Europe), anti-rat 528 
NL493 (R&D Systems, USA)), and DAPI (Life Technologies Europe B.V., Switzerland, 529 
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1:1000) for 1 h at room temperature. Slides were washed twice with PBS before they 530 
were mounted with Dako glycergel mounting medium (Dako, Switzerland). Sections were 531 
visualized on a Leica DM 5500B fluorescence microscope and images processed with 532 
ImageJ. 533 
Statistical analysis 534 
Statistics were performed using unpaired Student‘s t-test, ANOVA, or Two-Way-ANOVA 535 
(GraphPad Prism version 7, GraphPad, San Diego, CA) and R programming 536 
environment including the nlme, visreg, data.table, car, lmtest, and forestplot packages. 537 
P < 0.05 was considered significant. 538 
The identification of predictors for iFGF23 variation in the SKIPOGH population was 539 
performed using linear mixed models with random intercept. The distribution of all 540 
parameters was analyzed in histograms. Due to a heavily skewed distribution, IL-6, IL-541 
10, IFNγ and IL1-β were log-transformed. All parameters were centralized and then 542 
normalized by their standard deviations. Linear or nonlinear relationship of each variable 543 
with iFGF23 was assessed using a component residual plot. However, all parameters 544 
were considered linear. Assumptions on the within-group error were checked with plots 545 
of the standardized residuals versus fitted values and a Q-Q plot of the residuals. The 546 
assumptions on the random effects were checked with a Q-Q plot of the random effects. 547 
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Figure legends 587 
Figure 1 588 
Identification of plasma iFGF23 predictors in a human cohort. (a) Forest plot 589 
showing the fixed effects calculated for all predictors used in the mixed linear model for 590 
the subpopulation of 429 participants after all the exclusion criteria applied. Fixed effect 591 
estimates (β), standard error, ratio between the estimates and their standard errors (t-592 
value), and associated p-value from a t-distribution. The parameters are ordered by fixed 593 
effect estimates. (b) Association between plasma TNF and iFGF23 in the SKIPOGH 594 
cohort in a subpopulation of 429 participants after all the exclusion criteria applied. The 595 
regression line and confidence band were obtained from the linear mixed model 596 
containing all the predictors. 597 
Figure 2 598 
FGF23 and inflammation in Pkd1 KO mice. Plasma FGF23 (a) and TmP/GFR (b) as 599 
well as renal Tnf (e) and renal Tgfb (f) mRNA expression relative to 18SrRNA in Pkd1fl/fl, 600 
cre- (white squares) and Pkd1fl/fl, cre+ (black squares) animals after 6 and 12 weeks. 601 
Phosphorylation of NFκB p65 (g) in the nuclear fraction of total kidney protein 602 
homogenates in Pkd1fl/fl, cre- (white squares) and Pkd1fl/fl, cre+ (black squares) animals 603 
after 12 weeks. Renal (f) and bone (g) Fgf23 mRNA expression relative to 18SrRNA in 604 
Pkd1fl/fl, cre- (white squares) and Pkd1fl/fl, cre+ (black squares) animals after 12 weeks. 605 
ND = not detected. Two-way ANOVA with Bonferroni correction (a - d) or unpaired t-test 606 
(e - g), * p<0.05. 607 
Figure 3 608 
TNF neutralization lowers FGF23 in Pkd1 KO mice. Plasma TNF (a), iFGF23 (b), 609 
phosphate (c), and urea (d) levels, bone (e) and renal (f) Fgf23, renal Tnf (g), and renal 610 
Tgfb (h) mRNA expression relative to Hprt as well as abundance of NaPi-IIa (i) at the 611 
renal BBM relative to β-actin 24 hours after injection of 0.5mg isotypic IgG control or anti-612 
TNF neutralizing antibodies in 11-12 weeks old Pkd1fl/fl, cre- (white squares) and Pkd1fl/fl, 613 
cre+ (black squares) animals. ND = not detected. Two-way ANOVA with Bonferroni 614 
correction * p<0.05. 615 
Figure 4 616 
TNF stimulates FGF23 in vivo and in vitro. Plasma iFGF23 (a), TNF (b), phosphate 617 
(c), creatinine (d), urea (e) and FEP (f) as well as bone (g), spleen (h) thymus (i) and 618 
bone marrow Fgf23 mRNA expression relative to Hprt (g,h) or 18SrRNA (i,j) 48 hours 619 
after two consecutive injection of vehicle or 2 μg recombinant mouse TNF in 12 weeks 620 
old wild type mice. Unpaired t-test * p<0.05. Fold increase of Fgf23 (k), Dmp1 (l), Galnt3 621 
(m), and Nurr1 (n) mRNA expression compared to untreated control in primary murine 622 
osteocytes after stimulation with 1,25(OH)2D (white squares) or 10ng/ml TNF (black 623 
squares) for 24 hours. Single experiments were normalized to their untreated control 624 
(dashed line = 1). Number of independent experiments 9-10; One-way ANOVA with 625 
Bonferroni correction * p<0.05 compared to 1,25(OH)2D treated cells, # p<0.05 compared 626 
to untreated cells. 627 
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Figure 5 628 
TNF neutralization lowers plasma iFGF23 in mice with oxalate nephropathy. 629 
Oxalate-nephropathy was induced in wild type mice. Plasma iFGF23 (a), plasma TNF 630 
(b), renal Tnf (c) mRNA expression relative to Hprt, plasma phosphate (d), urinary 631 
phosphate to creatinine ratio (e), plasma creatinine (f) and plasma urea (g) 48 hours after 632 
injection of 0.5 mg isotypic IgG control or anti-TNF neutralizing antibodies in control diet 633 
(white squares) and oxalate nephropathy (black squares) induced mice. One-way 634 
ANOVA with Bonferroni correction * p<0.05. 635 
Figure 6 636 
Colonic inflammation increases plasma iFGF23 via TNF in Il-10 KO mice. Plasma 637 
iFGF23 (a) levels and colonic Tnf (b) mRNA expression relative to 18SrRNA in 14 weeks 638 
old Il-10+/+ and Il-10-/- mice. Plasma iFGF23 (c), phosphate (d), creatinine (e), and urea 639 
(f) levels as well as abundance of NaPi-IIa at the renal BBM 48 hours after injection of 640 
0.5 mg isotypic IgG control or anti-TNF neutralizing antibodies in 12 weeks old Il-10-/- 641 
mice. Unpaired t-test * p<0.05. 642 
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Identification of plasma iFGF23 
predictors in a human cohort. (a) 
Forest plot showing the fixed effects 
calculated for all predictors used in 
the mixed linear model for the 
subpopulation of 790 participants 
without drug intake criteria applied. 
Fixed effect estimates (β), standard 
error, ratio between the estimates and 
their standard errors (t-value), and 
associated p-value from a t-
distribution. (b) Association between 
plasma TNF and iFGF23 in the 
SKIPOGH cohort in a subpopulation 
of 790 participants after all the 
exclusion criteria applied. The 
regression line and confidence band 
were obtained from the linear mixed 




Baseline characteristics of Pkd1 KO mice. Two-kidney
per body weight ratio (a), Pkd1 gene expression
normalized to Pkdfl/fl, cre- mice (6 weeks) (b), plasma
iFGF23 (c), plasma PTH (d) and plasma urea (d) as well as
Runx-2 (e, f) mRNA expression relative to 18SrRNA in
kidney and bone in Pkd1fl/fl, cre- (white squares) and
Pkd1fl/fl, cre+ (black squares) animals at the age of 6 and
12 weeks. Two-way ANOVA with Bonferroni correction (a-
d, f) or unpaired t-test (e), * p<0.05.
Figure S3
Expression of inflammation markers in the kidney of Pkd1 KO mice. Renal Il1b (a), and
renal Il6 (b) mRNA expression relative to 18SrRNA in Pkd1fl/fl, cre- (white squares) and
Pkd1fl/fl, cre+ (black squares) animals at the age of 6 and 12 weeks. Two-way ANOVA with






(a, d, g, j), plasma
cFGF23 (b, e, h, k) and
iFGF23/cFGF23 ratio (c,

































































Bone and renal Nurr1 mRNA expression in Pkd1 KO mice. Nurr1 mRNA expression relative to 18SrRNA in kidney (a)
and bone (b) in Pkd1fl/fl, cre- (white squares) and Pkd1fl/fl, cre+ (black squares) animals at the age of 6 and 12 weeks.
Unpaired t-test (a), or Two-way ANOVA with Bonferroni correction (b), * p<0.05.
Figure S6
Colocalization of Nurr1 and FGF23 in Pkd1 kidneys.
Immunofluorescence staining for FGF23 (green), Nurr1
(red), and DAPI (blue, cell nuclei) merge and single
channels in kidneys of 12 weeks old Pkd1fl/fl, cre- (a-d),
Pkd1fl/fl, cre+ (e-h) and Pkd1fl/fl, cre+ incubated with
secondary antibodies alone (i). Original magnification (a, c,
e, g) 400x (scale bar 50 μm) and (b, d, f, h) 1000x (scale
bar 20 μm).
Figure S7
1,25 (OH)2 vitamin D3 dependent Fgf23 expression in
MC3T3-E1 cells under hypoxic conditions. MC3T3-E1 cells
were differentiated for two weeks along the osteogenic
lineage. Subsequently, cells were supplemented for 24 or 48
hours with 10nM 1,25 (OH)2 vitamin D3 and incubated under
hypoxic (0.2% oxygen) or normoxic conditions. Fgf23 (a),
Car9 (b), and Phd2 (c) mRNA expression relative to 18SrRNA.
Mean ±SD; 3 independent experiments; ANOVA with
Bonferroni correction, * p<0.05.
